Therapeutic interventions in sepsis: current and anticipated pharmacological agents

Related Experiment Video

Updated: Apr 27, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

9.4K

Prashant Shukla1, G Madhava Rao, Gitu Pandey

  • 1Pharmaceutics Division, Preclinical South PCS 002/011, CSIR - Central Drug Research Institute, Lucknow, India.

British Journal of Pharmacology
|July 1, 2014
PubMed

Insights

Sepsis treatment is evolving, with statins showing promise and novel drug delivery systems like nanoparticulate carriers offering new therapeutic avenues. Research focuses on effective interventions for both hypo- and hyperinflammatory sepsis states.

Area of Science:

  • Critical care medicine
  • Pharmacology
  • Biomedical engineering

Background:

  • Sepsis is a life-threatening multisystem response to infection.
  • The withdrawal of recombinant human-activated protein C (rAPC) necessitates new therapeutic strategies.
  • Existing experimental sepsis treatments often fail in clinical settings.

Purpose of the Study:

  • To review current and emerging therapeutic interventions for sepsis.
  • To discuss novel drug delivery systems for sepsis treatment.
  • To evaluate the potential of statins and nanoparticulate carriers in sepsis management.

Main Methods:

  • Literature review of experimental and clinical studies on sepsis therapeutics.
  • Critical analysis of drug delivery strategies, including nanoparticulate carriers.
  • Evaluation of ongoing clinical trials for sepsis treatments.

Main Results:

  • Statins are under investigation as a potential sepsis treatment.
  • Nanoparticulate carriers show potential for LPS neutralization and targeted drug delivery.
  • Many agents effective in experimental sepsis lack clinical validation.

Conclusions:

  • Developing effective sepsis therapies requires addressing both inflammatory states.
  • Advanced drug delivery systems offer promising avenues for sepsis treatment.
  • Continued research into novel molecules and delivery strategies is crucial for improving sepsis outcomes.

More Related Videos

Cecal Ligation Puncture Procedure11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

55.2K
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

19.3K

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
258
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K